Literature DB >> 2502520

Procoagulant activity of human neuroblastoma cell lines, in relation to cell growth, differentiation and cytogenetic abnormalities.

N Esumi1, S Imashuku, K Tsunamoto, S Todo, S Misawa, T Goto, Y Fujisawa.   

Abstract

Procoagulant activity (PCA) was investigated in relation to cell growth, differentiation, and cytogenetics in seven human neuroblastoma cell lines. Before 5-bromodeoxyuridine (BrdUrd) treatment, PCA was notably heterogeneous, with the highest activity in NCG (S-type in morphology) 40- to 100-fold greater than the lowest activity in SK-N-DZ (N-type). PCA was not related to 1p abnormalities. After BrdUrd treatment at 5 micrograms/ml for 6 days, PCA increased 6.8-fold in GOTO and 2.7-fold in SK-N-DZ with associated growth inhibition and morphological changes (I-type morphology converted to S-type in GOTO and N-type converted to an advanced N-type in SK-N-DZ). In contrast, only growth suppression was observed in 2 other cell lines, and no changes in PCA, growth or morphology were induced in the remaining 3 cell lines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502520      PMCID: PMC5917761          DOI: 10.1111/j.1349-7006.1989.tb02333.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  22 in total

1.  Antimetastatic effects associated with platelet reduction.

Authors:  G J Gasic; T B Gasic; C C Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  1968-09       Impact factor: 11.205

2.  Platelet aggregating activity mediated by thrombin generation in the NCG human neuroblastoma cell line.

Authors:  N Esumi; S Todo; S Imashuku
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

3.  Activation of blood coagulation in cancer: Trousseau's syndrome revisited.

Authors:  F R Rickles; R L Edwards
Journal:  Blood       Date:  1983-07       Impact factor: 22.113

4.  Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII.

Authors:  U Seligsohn; B Osterud; S I Rapaport
Journal:  Blood       Date:  1978-11       Impact factor: 22.113

5.  Relationship between cellular procoagulant activity and metastatic capacity of B16 mouse melanoma variants.

Authors:  L C Gilbert; S G Gordon
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

6.  Cancer procoagulant in human tumor cells: evidence from melanoma patients.

Authors:  M B Donati; C Gambacorti-Passerini; B Casali; A Falanga; P Vannotti; G Fossati; N Semeraro; S G Gordon
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

7.  Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis.

Authors:  E Bastida; A Ordinas; G Escolar; G A Jamieson
Journal:  Blood       Date:  1984-07       Impact factor: 22.113

8.  Cytogenetic features of human neuroblastomas and cell lines.

Authors:  G M Brodeur; A A Green; F A Hayes; K J Williams; D L Williams; A A Tsiatis
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

9.  5-bromodeoxyuridine-induced differentiation of a neuroblastoma.

Authors:  D Schubert; F Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1970-09       Impact factor: 11.205

10.  Effects of phorbol ester tumor promoters and nerve growth factor on neurite outgrowth in cultured human neuroblastoma cells.

Authors:  W Spinelli; K H Sonnenfeld; D N Ishii
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

View more
  3 in total

1.  Distinct mechanism of human neuroblastoma cell adhesion to fibronectin.

Authors:  T Yoshihara; S Ikushima; Y Shimizu; N Esumi; S Todo; M J Humphries; S Imashuku
Journal:  Clin Exp Metastasis       Date:  1991 Jul-Aug       Impact factor: 5.150

2.  Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line.

Authors:  Hirofumi Nakanishi; Kiyoko Yoshioka; Susumu Joyama; Nobuhito Araki; Akira Myoui; Shingo Ishiguro; Takafumi Ueda; Hideki Yoshikawa; Kazuyuki Itoh
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

3.  PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.

Authors:  Lei Qi; Hidemi Toyoda; Dong-Qing Xu; Ye Zhou; Naoto Sakurai; Keishirou Amano; Kentaro Kihira; Hiroki Hori; Eiichi Azuma; Yoshihiro Komada
Journal:  Cancer Cell Int       Date:  2015-09-29       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.